Sesen Bio — Eleven Biotherapeutics — Investor Presentation (May 2017)
34 slides from Sesen Bio's investor presentation, May 1, 2017
Slide 1: Targeting Cancer with POWER+PRECISION
© 2017 Eleven Biotherapeutics. All rights reserved. May 2017 © 2017 Eleven Biotherapeutics. All rights reserved. Targeting Cancer with POWER+PRECISION™
Slide 2: Forward-looking statements
© 2017 Eleven Biotherapeutics. All rights reserved. This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future o
Slide 3: How We Got Here: Eleven Biotherapeutics
© 2017 Eleven Biotherapeutics. All rights reserved. How We Got Here: Eleven Biotherapeutics • Cambridge, Massachusetts-based company founded in 2010 by Flagship Pioneering and Third Rock Ventures to engineer protein therapeutics for a wide variety of disorders ‒ Formed with $55 million in venture ca
Slide 4: Investment Rationale
© 2017 Eleven Biotherapeutics. All rights reserved. Investment Rationale 4 Broad pipeline of locally and systemically-administered product candidates • ProxiniumTM, in development for squamous cell head and neck (SCCHN) - Demonstrated anti-tumor activity in prior Phase 1 and Phase 2 studies - Plan t
Slide 5: Product Pipeline
© 2017 Eleven Biotherapeutics. All rights reserved. Product Pipeline Product Candidate Payload Indication Preclinical Ph 1 Ph 2 Ph 3 Locally-administered TPTs Vicinium ETA BCG refractory high-grade NMIBC Proxinium (combination with checkpoint inhibitor) ETA Late-stage SCCHN Systemically-administered
Slide 6: Targeted Protein Therapeutics: Overcoming the Limitations of Existing ADCs
© 2017 Eleven Biotherapeutics. All rights reserved. Targeted Protein Therapeutics: Overcoming the Limitations of Existing ADCs • Deliver a greater amount of drug to tumor bed with deeper penetration ‒ Engineered utilizing antibody fragments (single chains and Fabs) vs. intact Mabs • Kill a broader a
Slide 7: Fit for Purpose Design
© 2017 Eleven Biotherapeutics. All rights reserved. Fully biologic constructs that are designed through recombination of key components as single gene-fused proteins One Targeting Moiety + Linker + Protein toxin Furin Cleavable Non- Cleavable scFv Fab Diabody DeBouganin ETA (Pseudomonas Exotoxin A)
Slide 8: Vicinium in Phase 3 for the Treatment of High-Grade NMIBC
© 2017 Eleven Biotherapeutics. All rights reserved. In Phase 3 for the Treatment of High-Grade NMIBC 8
Slide 9: Vicinium: Targeting High-Grade NMIBC
Vicinium: Targeting High-Grade NMIBC C C EpCAM target on NMIBC • EpCAM over-expressed in >98% of high grade NMIBCs – no companion diagnostic needed • Minimal to no EpCAM expression on normal bladder cells • Vicinium binds specifically to EpCAM+ cells Truncated Pseudomonas exotoxin A (ETA) • Potent p
Slide 10: Vicinium: Mechanism of Action
© 2017 Eleven Biotherapeutics. All rights reserved. Vicinium: Mechanism of Action 10
Slide 11: Significant Unmet Need in NMIBC
© 2017 Eleven Biotherapeutics. All rights reserved. Significant Unmet Need in NMIBC • Bladder Cancer - 2nd most common cancer of genitourinary system ‒ Ninth most common cancer diagnosed worldwide (~430,000 new patients/year)1 ‒ There are 79,000 new diagnoses of bladder cancer in the U.S. each year
Slide 12: NMIBC: Recent Events Underscore Unmet Medical Need
© 2017 Eleven Biotherapeutics. All rights reserved. NMIBC: Recent Events Underscore Unmet Medical Need • In November 2016, Sanofi announced plans to stop producing BCG in mid-2017 due to manufacturing challenges • In November 2016 the FDA released draft guidance: 12 ‒ Our Phase 3 design is consisten
Slide 13: Vicinium: Phase 1 Clinical Results
© 2017 Eleven Biotherapeutics. All rights reserved. Vicinium: Phase 1 Clinical Results • 64 NMIBC patients with Grade 2 or 3 BCG refractory or intolerant ‒ 95% of the patients had two or more bladder cancer recurrences ‒ 55% had 2 or more BCG cycles ‒ Only 5 of 64 were intolerant • Trial design • Tr
Slide 14: Vicinium: Phase 2 Clinical Results
© 2017 Eleven Biotherapeutics. All rights reserved. Vicinium: Phase 2 Clinical Results • A total of 46 patients received 1 induction cycle of 6 (cohort 1) or 12 (cohort 2) weekly intravesical instillations of 30 mg ‒ BCG refractory or intolerant carcinoma in situ (CIS) subjects • CIS is most aggress
Slide 15: • Amount of prior BCG had no impact on responses week arm had the
© 2017 Eleven Biotherapeutics. All rights reserved. • Amount of prior BCG had no impact on responses 12 week arm had the highest number of patients that had 2 or more courses of BCG • 10 of 22 patients in cohort #1 had ≥2 courses of BCG • 4 (40%) were CR at 3 months and 2 (20%) were a CR past 18 mon
Slide 16: Vicinium: Phase 2 Clinical Results
© 2017 Eleven Biotherapeutics. All rights reserved. CIS with or without Ta, T1 CIS with or without Ta, T1 Treatment Arm B Subjects (N=20) Treatment Arm A Subjects (N=20) 6 Week Induction 12 Week Induction Increased Area Affected n=3 Stable Disease N=4 Partial Response N=4 Complete Responders N=9 % R
Slide 17: Adverse Events: Phase 1 and 2 Trials
© 2017 Eleven Biotherapeutics. All rights reserved. Adverse Events: Phase 1 and 2 Trials • No significant toxicity or tolerability issues ‒ Generally well tolerated ‒ No subjects unable to complete treatment • Phase 1 Trial ‒ 31% of subjects experienced an AE related to treatment ‒ 98% of all AEs we
Slide 18: VISTA: Vicinium Phase 3 Registration Study
© 2017 Eleven Biotherapeutics. All rights reserved. VISTA: Vicinium Phase 3 Registration Study • Enrolling 134 patients (including 77 patients CIS) with BCG refractory or relapsed high-grade NMIBC (CIS and/or Papillary Tumors) at over 65 centers in the U.S. and Canada • Increased induction and maint
Slide 19: Treatment of Late-Stage SCCHN
© 2017 Eleven Biotherapeutics. All rights reserved. Treatment of Late-Stage SCCHN Phase 1/2a Initiation Expected in 2H 2017 19
Slide 20: Proxinium and late-stage SCCHN
© 2017 Eleven Biotherapeutics. All rights reserved. • Single chain anti-EpCAM antibody fragment fused with ETA • Late-stage SCCHN is dominated by the primary tumor ‒ 40-60% of deaths result from local or regional disease1 ‒ 90% of patients with disseminated disease die as a result of uncontrolled di
Slide 21: Proxinium: Phase 1 Trials
© 2017 Eleven Biotherapeutics. All rights reserved. Proxinium: Phase 1 Trials VB4-101 VB4-101A Location Russia Brazil Schedule Daily x 5 q 28 days Weekly x 4 MTD 200 µg 700 µg N 24 20 EpCAM+ 17 18 Response Criteria – based on target lesion(s) • Investigator’s measurements • Investigator’s overall as
Slide 22: Proxinium: Phase 1 Clinical Trial Results
© 2017 Eleven Biotherapeutics. All rights reserved. Proxinium: Phase 1 Clinical Trial Results • EpCAM expression was not an inclusion criterion ‒ EpCAM+ subjects were 71% (Russia) and 90% (Brazil) ‒ None of the evaluable EpCAM- subjects (n=8) from either trial responded • Three out of the four patie
Slide 23: Proxinium: Responses in Targeted & Non-Targeted Tumors
© 2017 Eleven Biotherapeutics. All rights reserved. After four weeks of treatment Targeted tumor cell cytotoxicity may lead to cross-priming and immune therapy (T cell-mediated killing) of non-targeted tumors Injected Tumor Subject A: Subject B: Pre-treatment Injected Tumor Non-Targeted Tumor Proxin
Slide 24: Proxinium: Phase 2 Trial
© 2017 Eleven Biotherapeutics. All rights reserved. • Reduction in the bidirectional size of the principle targeted tumor observed in 71% (10/14) of the evaluable subjects ‒ RECIST criteria not employed • In 5 subjects with multiple tumors, growth control of the initial treated tumor was achieved in
Slide 25: Proxinium: Phase 2/3 Clinical Trial Data
© 2017 Eleven Biotherapeutics. All rights reserved. Proxinium: Phase 2/3 Clinical Trial Data Proxinium + BSC vs. BSC summarized Phase 2 and Phase 3 data1 RECIST criteria not employed Progression Stable Disease Response 1Only subjects with baseline and post-treatment tumor measurements are included (
Slide 26: Immune Checkpoint Combinations
© 2017 Eleven Biotherapeutics. All rights reserved. Immune Checkpoint Combinations • Clinical trials suggest that Proxinium may be promoting host anti-tumor immune responses • Immune checkpoint therapy requires an ongoing immune response ‒ Effective in “hot” (inflamed) tumors often associated with s
Slide 27: Proxinium: ICD-induced DAMPs
© 2017 Eleven Biotherapeutics. All rights reserved. Proxinium: ICD-induced DAMPs Proxinium mediates ICD and induces DAMPs suggesting that it could promote host cellular anti-tumor immune responses Control Proxinium VB4-4B5 9 hrs 5.7 ± 0 8.8 ± 0.1 5.8 ± 0.3 18 hrs 10.3 ± 0.3 17. 05 ± 0.35 10.5 ± 0.1
Slide 28: Proxinium: Robust Clinical Development Plan
© 2017 Eleven Biotherapeutics. All rights reserved. • Observed responses in non-injected tumors during prior clinical trials and evidence from preclinical in vitro and animal studies suggest that Proxinium generates a host anti-tumor immune response that may improve the efficacy of checkpoint inhibi
Slide 29: De-Immunized Systemic Product Pipeline
© 2017 Eleven Biotherapeutics. All rights reserved. De-Immunized Systemic Product Pipeline Bouganvillea sp. deBouganin toxin 29
Slide 30: deBouganin: Next Generation Payload
© 2017 Eleven Biotherapeutics. All rights reserved. deBouganin: Next Generation Payload • Highly potent plant toxin ‒ Picomolar killing, avoidance of MDR, potentially effective against cancer stem cells ‒ Safety profile provides broad therapeutic window • Engineered a de-immunized variant for system
Slide 31: Corporate
© 2017 Eleven Biotherapeutics. All rights reserved. Corporate 31
Slide 32: Experienced Leadership Team
Experienced Leadership Team Steve Hurly President, CEO, and Director Arthur DeCillis, MD Chief Medical Officer John McCabe, CPA Chief Financial Officer Greg Adams, PhD Chief Scientific Officer Glen MacDonald, PhD Chief Technology Officer Wendy L. Dixon, PhD - Chair Abbie C. Celniker, PhD Paul Chaney
Slide 33: Upcoming Milestones
© 2017 Eleven Biotherapeutics. All rights reserved. Initiate Proxinium / Checkpoint SCCHN Phase 2 trial 2H 2017 Vicinium NMIBC Phase 3 complete enrollment 2H 2017 Submit IND to FDA for systemic product candidate VB6-845d Q1 2018 Vicinium NMIBC Phase 3 topline data 2018 Upcoming Milestones 33
Slide 34: Targeting Cancer with POWER+PRECISION
© 2017 Eleven Biotherapeutics. All rights reserved. © 2017 Eleven Biotherapeutics. All rights reserved. Targeting Cancer with POWER+PRECISION™
Eleven Biotherapeutics — Investor Presentation (May 2017) on 6ix